Muscle News and Research

RSS

Study aims at determining optimal dose of nab-paclitaxel with carboplatin as first-line therapy for NSCLC

The June edition of the Journal of Thoracic Oncology features a study aimed at determining the optimal dose of the chemotherapy drug nab-paclitaxel with carboplatin as a first-line therapy in patients with non-small cell lung cancer. Results will provide researchers with a data needed to guide a phase 3 trial.

16 Jun 2010

FDA cautions on infant overdose risk with liquid Vitamin D

The Food and Drug Administration today alerted parents and caregivers that some liquid Vitamin D supplement products are sold with droppers that could allow excessive dosing of Vitamin D to infants.

16 Jun 2010

Innovacell Biotechnologie commences enrollment in urocell Phase IIb study for bladder weakness

"First patient in" is the call from the Innsbruck firm, Innovacell Biotechnologie AG, as the first patient was recruited at the MHAT Plovdiv clinic in Bulgaria for the Phase IIb study of the advanced therapy medicinal product, urocell®. The clinical study will be conducted, beside Bulgaria, in the Czech Republic, Germany, Poland and Romania at more than 50 clinics.

15 Jun 2010

2,300 researchers under one roof at American Society of Echocardiography 21st Annual Scientific Sessions

Research released today at the American Society of Echocardiography (ASE) 21st Annual Scientific Sessions unveiled findings that will have a significant impact on the diagnosis and treatment of heart disease and the application of echocardiography in the future.

15 Jun 2010

Noninvasive carotid artery ultrasound helps avoid coronary angiography

New research from NYU Langone Medical Center shows that a simple, inexpensive and noninvasive carotid artery ultrasound of the neck can be used as a preliminary diagnostic tool for coronary artery disease (CAD). This may be an alternative to the standard, expensive and more invasive coronary angiography.

15 Jun 2010

Parkinson’s disease linked to gene variant and pesticide: Study

Researchers from France reported in their new study that bad genes and exposure to certain banned pesticides could be blamed for development of Parkinson’s disease in men. In their study, published in the Archives of Neurology journal they show that men exposed to pesticides such as DDT and who had inherited genes for Parkinson’s disease were three and a half times more likely to develop Parkinson's than those with the normal version of the gene.

14 Jun 2010

Telormedix initiates Phase I/II clinical study of TMX-101 for treating NMIBC

Telormedix, a clinical stage biopharmaceutical company focused on targeted immunity in the treatment of cancer and other diseases, today announced the start of a Phase I/II clinical study of TMX-101 for the treatment of Non-Muscle Invasive Bladder Cancer. TMX-101 is an immunotherapeutic compound and Telormedix has already recruited the first patients for this clinical study.

14 Jun 2010

Olfactory function tests could help in treating patient in early stages of PD

A fast, simple and non invasive test of the ability to smell may be an important tool to screen people who are likely to develop Parkinson's disease, in which motor symptoms only become evident at a later stage of the disease, a German scientist will tell the annual conference of the European Society of Human Genetics today (Saturday).

14 Jun 2010

Botox reduces short-term pain in thoracic outlet syndrome patients

Made popular for its ability to smooth wrinkles when injected into the face, Botox - a toxin known to weaken or paralyze certain nerves and muscles - may have another use that goes beyond the cosmetic.

11 Jun 2010

Raw and cooked gingers reduce pain associated with muscle injury by 24%: Reed's

Reed's, Inc., maker of the top-selling sodas in natural food stores nationwide, commented today on a recent study in The Journal of Medicine that both raw and cooked ginger reduce pain associated with muscle injury by about 24%, compared with placebo. The study was supported by the McCormick Science Institute.

10 Jun 2010

Researchers differentiate human stem cells to become heart cells with cardiomyopathy

Researchers at Mount Sinai School of Medicine have for the first time differentiated human stem cells to become heart cells with cardiomyopathy, a condition in which the heart muscle cells are abnormal. The discovery will allow scientists to learn how those heart cells become diseased and from there, they can begin developing drug therapies to stop the disease from occurring or progressing. The study is published in the June 9th issue of Nature.

10 Jun 2010

UC emergency medicine assistant professor compares efficacy of two seizure medications to prevent SE

When seizures strike, the most immediate goal for caregivers is to get appropriate medication to the patient as quickly as possible to stop the seizing activity. In a paper published in the June Academic Emergency Medicine, UC emergency medicine assistant professor Jason McMullan, MD, found that the best means of stopping status epilepticus may be with the least direct medication.

10 Jun 2010

Today's multi-touch systems may lead people to MSD: Researchers

The evolution of computer systems has freed us from keyboards and now is focusing on multi-touch systems, those finger flicking, intuitive and easy to learn computer manipulations that speed the use of any electronic device from cell phones to iPads. But little is known about the long-term stresses on our bodies through the use of these systems.

10 Jun 2010

Fero Industries enters into Asset Acquisition Agreement with GVEST

Fero Industries, Inc. is pleased to announce that it has entered into an Asset Acquisition Agreement with GVEST Inc., an Ontario Corporation, for the acquisition of certain intellectual property and other associated rights related to the production, marketing, and distribution of Sucanon, a treatment for Type II diabetes.

10 Jun 2010

Repligen's fiscal 2010 total revenue decreases to $20,971,000

Repligen Corporation today reported results for the fourth quarter and fiscal year 2010, ended March 31, 2010. Total revenue for the year was $20,971,000 compared to total revenue of $29,362,000 for fiscal year 2009 ended March 31, 2009.

9 Jun 2010

Sonic hedgehog helps regenerate critical nerve that runs along prostate: Research

After men have surgery to remove a cancerous prostate gland, up to 80 percent of them will lose the ability to have an erection because of damage to a critical nerve that runs along the prostate.

9 Jun 2010

4% of South Asian people carry mutated gene that causes heart failure

One in 25 people from India and other south Asian countries carries a mutated gene that causes heart failure.

9 Jun 2010

Psychological intervention program teaches breast cancer patients how to cope with the disease

A psychological intervention program designed for breast cancer patients reduces the risk of dying if the cancer recurs, new research shows. The study is the latest in a series at Ohio State University that have shown that an intervention program that teaches patients how to cope with the disease can boost their health, well-being and even their chances of survival.

9 Jun 2010

Researchers look at exercise as new way to slow degenerative processes of ALS

University of Alberta researchers are looking at exercise as a new way to slow the degenerative processes of ALS, commonly known as Lou Gehrig's disease. Dr. Kelvin Jones, a recipient of this year's ALS Canada Discovery Grant, has been pioneering research in this field for four years, using mice genetically altered to present familial ALS. He's found that exercise has a positive impact on the mice, slowing the disease significantly.

9 Jun 2010

GTx presents quality of life results from Ostarine Phase IIb study in cancer cachexia patients at ASCO 2010

GTx, Inc. today presented additional results from the Ostarine™ Phase IIb study demonstrating an improvement in quality of life (fatigue and anorexia) in cancer patients with muscle wasting (cancer cachexia) who demonstrated improvement in functional performance as measured by stair climb. Ostarine (GTx-024) is GTx's lead selective androgen receptor modulator (SARM) which the company is developing for the treatment of cancer cachexia.

8 Jun 2010

Muscle News and Research

Study aims at determining optimal dose of nab-paclitaxel with carboplatin as first-line therapy for NSCLC

FDA cautions on infant overdose risk with liquid Vitamin D

Innovacell Biotechnologie commences enrollment in urocell Phase IIb study for bladder weakness

2,300 researchers under one roof at American Society of Echocardiography 21st Annual Scientific Sessions

Noninvasive carotid artery ultrasound helps avoid coronary angiography

Parkinson’s disease linked to gene variant and pesticide: Study

Telormedix initiates Phase I/II clinical study of TMX-101 for treating NMIBC

Olfactory function tests could help in treating patient in early stages of PD

Botox reduces short-term pain in thoracic outlet syndrome patients

Raw and cooked gingers reduce pain associated with muscle injury by 24%: Reed's

Researchers differentiate human stem cells to become heart cells with cardiomyopathy

UC emergency medicine assistant professor compares efficacy of two seizure medications to prevent SE

Today's multi-touch systems may lead people to MSD: Researchers

Fero Industries enters into Asset Acquisition Agreement with GVEST

Repligen's fiscal 2010 total revenue decreases to $20,971,000

Sonic hedgehog helps regenerate critical nerve that runs along prostate: Research

4% of South Asian people carry mutated gene that causes heart failure

Psychological intervention program teaches breast cancer patients how to cope with the disease

Researchers look at exercise as new way to slow degenerative processes of ALS

GTx presents quality of life results from Ostarine Phase IIb study in cancer cachexia patients at ASCO 2010

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News